The approved product is indicated for the treatment of adult patients with Multiple myeloma, in combination with Dexamethasone
Natural Capsules Limited's shareholding will be reduced to 89.99%
The audit was commenced for newly renovated manufacturing Block 1, Block 2, and Block 3
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
The new Beyfortus data are consistent with all data accumulated to date and confirm its strong profile
This artificial RNA ligase has higher thermostability than natural RNA ligase
First release of Rs.166 crores incentives under PLI scheme for pharmaceuticals
The new company will utilize Teijin's drug discovery research technologies, facilities, equipment and personnel.
There is a fast resurgence in the transplant activities post COVID
Subscribe To Our Newsletter & Stay Updated